Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Australia’s First Single-Cell Genomics Centre of Excellence Opens at Monash Health Translation Precinct
Through an innovative and entrepreneurial approach to genomics medicine, the Centre intends to accelerate scientific discoveries.   MELBOURNE, Australia and SOUTH SAN FRANCISCO, California, Sept. 4, 2015 – A partnership among Monash University, the University of Melbourne, the University of
View HTML
Toggle Summary Bill W. Colston Named to Fluidigm Board of Directors
Senior Biotechnology Leader with Broad Expertise in Life Science and Digital Health SOUTH SAN FRANCISCO, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Bill W. Colston to the company’s Board of Directors.
View HTML
Toggle Summary Brad Kreger Joins Fluidigm as Senior Vice President, Global Operations
SOUTH SAN FRANCISCO, Calif. , April 23, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Brad Kreger as Senior Vice President, Global Operations. In this role, Kreger leads global manufacturing, supply chain, demand planning, and distribution for
View HTML
Toggle Summary Caprion Biosciences Offers Mass Cytometry CRO Services to Advance Biomarker Discovery and Immune Monitoring
Mass cytometry services for pharmaceutical and biotechnology companies to accelerate development of new health insights SOUTH SAN FRANCISCO, Calif. and MONTREAL , Jan. 08, 2019 (GLOBE NEWSWIRE) -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory
View HTML
Toggle Summary Colin McCracken Joins Fluidigm as Chief Commercial Officer
SOUTH SAN FRANCISCO, Calif. , March 05, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer. McCracken will be responsible for leading all commercial activities, driving revenue growth in new and
View HTML
Toggle Summary CORRECTING and REPLACING - Fluidigm Announces Second Quarter 2019 Financial Results
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass Cytometry Panel Kits, Advanced CyTOF Software Introduction of Nanoscale Automated RNA-Seq NGS
View HTML
Toggle Summary CyTOF Inventors Receive Prestigious Science and Technology Award from the Human Proteome Organization (HUPO)
Industry-Leading CyTOF Technology Recognized at the 18th Annual HUPO World Congress for Delivering Unprecedented Proteomic Insight at Single-Cell Resolution SOUTH SAN FRANCISCO, Calif. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- The Human Proteome Organization (HUPO), an international scientific
View HTML
Toggle Summary David King Joins Fluidigm as Vice President, Research and Development, Genomics
SOUTH SAN FRANCISCO, Calif. , June 26, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of David King as Vice President, Research and Development, Genomics. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite , King
View HTML
Toggle Summary Dvs Sciences Introduces The Cytof® 2
DVS Sciences introduces the CyTOF® 2 mass cytometer and new MaxPar® Panel Kits for transformational high‐parameter single cell analysis
View HTML
Toggle Summary European Mass Cytometry Consortium Brings CyTOF Technology to Leading Universities to Advance Clinical Research
SOUTH SAN FRANCISCO, Calif. , May 04, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that leading research institutions in the UK have partnered to acquire and implement seven Helios™ mass cytometry systems to empower life-changing discoveries in human health.
View HTML